Awaiting development: Guidance and quality standards
Showing 301 to 306 of 306
| Title | Type |
|---|---|
| Zavegepant for treating acute migraine [TSID11998] | Technology appraisal guidance |
| Zilugisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [TSID12252] | Technology appraisal guidance |
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573] | Technology appraisal guidance |